InGeNA welcomes our new member Oncoparse

InGeNA warmly welcomes our new member, Oncoparse.

Oncoparse is an early-stage genomics company developing next generation diagnostics to address critical blind spots in pancreatic cancer care. Our mission is to transform pancreatic cancer into a manageable condition by enabling earlier, faster, and more accurate diagnosis through cell-free DNA (cfDNA) testing.

Learn more about Oncoparse’s vital work at www.oncoparse.com/.